Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

April 2024

Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA

BMJ Open 2024;14:e072300 doi: 10.1136/bmjopen-2023-072300

Aymon R,

Unadjusted time to all-cause discontinuation was significantly longer with baricitinib treatment versus TNFi (estimated median prescription survival time of 704 days versus 448 days; log-rank P<0.01). This difference increased when only comparing differences for b/tsDMARD-naïve patients treated with baricitinib versus tofacitinib.

Keywords:

December 2022

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Ann Rheum Dis. 2022. Epub ahead of print [05/12/2022] doi: 10.1136/ard-2022-223356

Pope JE,

Balsa A,

Buch MH,

Li Z,

Nash P,

Poor G,

van der Helm-van Mil A,

Smolen, et al. provide a 2022 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs.

Keywords:

EULAR

October 2022

After JAK Inhibitor Failure: To Cycle Or To Switch, That Is The Question – Data From The JAK-Pot Collaboration of Registries

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222835

Inanc N,

Leeb BF,

Rotar Z,

Data from the JAK-pot collaboration of registries show that cycling JAKinibs and switching to a bDMARD appear to have similar effectiveness, after failing the first JAKinib.

Keywords:

July 2022

Efficacia degli inibitori del TNF, di abatacept, degli inibitori di IL6 e degli inibitori di JAK in 31.846 pazienti con artrite reumatoide in 19 registri della collaborazione "JAK-pot"

Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2022-222586

Inanc N,

Leeb BF,

Rotar Z,

Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.